CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 791 - 800 of 842
Study Number Lead Group Study Title CIRB Study Status
S1007 SWOG A Phase III; Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes; Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node; Endocrine Responsive Breast Cancer Adult CIRB - Late Phase Emphasis Available to Open
S1507 SWOG A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies Adult CIRB - Late Phase Emphasis Available to Open
S1914 SWOG A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC Adult CIRB - Late Phase Emphasis Available to Open
S1714 SWOG A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients Cancer Prevention and Control CIRB Available to Open
S0226 SWOG Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer Adult CIRB - Late Phase Emphasis Completed
S1823 SWOG A Prospective Observational Cohort Study To Assess miRNA 371 For Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors Cancer Prevention and Control CIRB Available to Open
S0106 SWOG A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) during Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 with Previously Untreated De Novo Acute Myeloid Leukemia (AML) Adult CIRB - Late Phase Emphasis Completed
S1404 SWOG A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma Adult CIRB - Late Phase Emphasis Available to Open
S0518 SWOG Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced; Poor Prognosis Carcinoid Patients Adult CIRB - Late Phase Emphasis Completed
S9910 SWOG Leukemia Centralized Reference Laboratories and Tissue Repositories Ancillary Adult CIRB - Late Phase Emphasis Completed
Displaying 791 - 800 of 842